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INTRODUCTION
The peptide neurotransmitter substance P (SP) binds
preferentially to the NK1 subtype of neurokinin recep-
tor (NK1R) to elicit various biological responses. SP also
binds to two other subtypes (i.e., NK2 and NK3) of
neurokinin receptors with lower affinities. Sequence
analysis of the cloned rat NK1R indicates that it belongs
to the heptahelical receptor family (Yokota et aI., 1989).
Elucidation of the molecular basis of subtype-specific
interaction between SP and NK1R will require the
localization of the binding domain. In the present
report, we have used mutagenesis and heterologous
expression approaches to show that part of the extracel-
lular NH2-terminal sequence is required for high affinity
binding of peptides. The cDNA encoding the human
NK1R was also cloned, and sequence comparison with
the rat NK1R reveals 22 amino acid substitutions.
Site-directed mutagenesis suggested that the 97th resi-
due in the second extracellular segment interacts with
some peptides but not others.
RESULTS AND DISCUSSION
The cloned rat NK1R, human NK1R and their mutants
were expressed in COS cells. To determine the binding
affinity of peptide agonists SP, substance K (SK) and
neurokinin B (NKB), competition binding experiments
were performed in the presence of 0.2 nM 125I-Bolton
Hunter labeled SP and various concentrations of pep-
tides using intact cells. Free 125I_SP was separated from
bound 125I_SP by glass fiber filters. The equilibrium
dissociation constant Kd was calculated from the ICso
value (Fig. 1).
Based on the amino acid sequence analysis, the
residues 1-31 are predicted to be on the extracellular
side. Two substitution mutants of rat NK1R were
constructed. With the S(1-13) mutant where the NH2-
terminal residues 1-13 of rat NK1R were substituted by
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the sequence MDYKDDDDKPW, a threefold decrease
in ligand binding affinity was observed (Table 1). With
the S(1-27) mutant where the NH2-terminal residues
1-27 of rat NK1R were substituted by the same se-
quence, the specific 125I_SP binding was further de-
creased (Kd > 100 nM). These data suggest that the
residues 14-27 are required for high affinity binding of
peptides to the NK1R.
Functional expression of both the rat and human
NK1R in COS cells indicated all three peptide agonists
have higher binding affinities at the human receptor
than the rat receptor (Table 1). This functional differ-
ence must be attributable to the sequence divergence
because the human NK1R has 22 amino acid residues
that are different from rat NK1R (Fong et aI., 1992).
The largest divergence is at position 97 where rat NK1R
contains a Val while human NK1R contains a Glu. The
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FIGURE 1 Inhibition of JlSI_SP binding to the human NKIR by
unlabeled peptide. The curves were calculated according to the
equation [CPM(L) - CPM(II-LM SP)]/[CPM(O) - CPM(lI-LM SP)] =
IC,./(L + IC,.) in which CPM(L) and CPM(O) represent bound IlSI_SP
in the presence and the absence of unlabeled peptide, respectively; L
represents the concentration of unlabeled peptide; and IC,. represents
the concentration of unlabeled peptide that causes 50% of inhibition.
For SP, Kd was calculated according to Kd(sp) = IC,. - [12SI-SP]. For
other peptides, Kd was calculated according toKd = IC,./(l + [12SI_SP]I
Kd(sp»,
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TABLE 1 Agonist binding afftnltles of two substitution mutants
of rat NK1 R, wild type rat NK1 R, a single amino acid
substitution mutant of rat NK1R, and human NK1R
Kd (nM), mean ± SEM (n)
Receptor SP SK NKB
Rat NKIR S(1-B) 10.7 ± 2.6 (2) 157 ± 30 (2)
Rat NKIR S(I-27) > 100 (3)
Rat NKIR 3.2 ± 0.7 (5) 55 ± 26 (3) 179 ± 11 (3)
Rat NKIR V97E 2.9 ± 0.7 (4) 58 ± 6 (3) 77 ± 21 (2)
HumanNKIR 0.7 ± 0.2 (4) 25 ± 6 (4) 57 ± 9 (4)
97th residue is predicted to be within the second
extracellular segment. A single amino acid substitution
of rat NK1R was constructed to place Glu at the Val
position by site-directed mutagenesis. Measurements of
binding affinities indicated that the affinity of NKB to
the mutant rat NK1R is similar to that for the human
NKIR, whereas the affinities of SP and SK are not
changed by the V97E substitution (Table 1). The rat
NIG receptor (Shigemoto et aI., 1990), for which NKB
has a high affinity (NKB > SK > SP), also contains a
Glu residue at the analogous position. These data
suggest that the Glu97 residue in the human NK1R is
involved in interaction with NKB but not SP or SK.
The present results indicate that the extracellular
domain of NK1 R comprises part of the peptide binding
domain. Previous studies on adrenergic and muscarinic
receptors have demonstrated that the binding domain
for these small molecules is in the bilayer domain
(O'Dowd et aI., 1989; Strader et aI., 1989; Wheatley et
aI., 1988). Because neurokinin peptides are about 10
times larger than acetylcholine and catecholamines, it is
not surprising that the peptide-receptor interaction
involves residues from the extracellular domain. Other-
studies using lectin or antibody are consistent with the
present conclusion. For example, concanavalin A re-
duces the affinity of SP binding (Takamatsu et aI., 1991).
Antibodies against the second and fourth extracellular
segments of NK2 receptor inhibit the binding of SP to
NK1R by cross-reaction (Parnet et aI., 1991). Further
mutagenesis experiments are required to fully under-
stand the basis of peptide-receptor interaction.
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